<p><strong>Pancreatitis</strong>: Has been reported in clinical trials. Discontinue promptly if pancreatitis is suspected. Do not restart if pancreatitis is confirmed. Consider other antidiabetic therapies in patients with history of pancreatitis.<br />
<strong>Hypoglycemia</strong>: When Dulaglutide is used with an insulin secretagogue (e.g., a sulfonylurea) or insulin, consider lowering the dose of the sulfonylurea or insulin to reduce the risk of hypoglycemia.<br />
<strong>Hypersensitivity Reactions</strong>: Serious hypersensitivity reactions (e.g., anaphylactic reactions and angioedema) have occurred. Discontinue Dulaglutide and promptly seek medical advice.<br />
<strong>Acute Kidney Injury</strong>: Monitor renal function in patients with renal impairment reporting severe adverse gastrointestinal reactions.<br />
<strong>Severe Gastrointestinal Disease</strong>: Use may be associated with gastrointestinal adverse reactions, sometimes severe. Has not been studied in patients with severe gastrointestinal disease and is not recommended in these patients.<br />
<strong>Diabetic Retinopathy Complications</strong>: Have been reported in a cardiovascular outcomes trial. Monitor patients with a history of diabetic retinopathy.</p>